Donate
T1International Statement on Freeze of Executive Actions

T1International Statement on Freeze of Executive Actions

Facebook Google LinkedIn Twitter

On January 20, President Biden issued a freeze on all new regulations that former President Trump had not finished implementing so his administration would have a chance to evaluate them and decide whether they should go into effect. These freezes are standard practice for a new administration taking over for a president of the opposite party; President Trump implemented a similar freeze on his first day in office in 2017.

One such regulation required that federally qualified health centers (FQHCs) that receive legally-required discounts on insulin through the federal 340B program "pass through" the full amount of that discount to patients. While this sounds like a beneficial policy for patients on the surface, it would not have had any impact on the list price of insulin, which is the primary cause of the insulin crisis -- and it would have made it harder for FQHCs to continue providing the same range of services they do now. Given that well over 2 million people living with with diabetes in the United States receive care from FQHCs, any negative impact on their ability to continue providing a wide range of services and care is cause for concern.

President Biden's regulatory freeze is being used to try to score ideological points from both the left and right, but patients are not pawns to be used for retweets. Like President Trump before him, President Biden has the power to hold the insulin manufacturers accountable for exploiting patients, and we expect him to use the tools available to him to lower the list price of insulin. T1International's stance remains the same as it was when the order was first released last year: If the president really wants to lower the price of insulin and address the crisis of high drug prices, he already knows the solution; the question is whether he has the political courage to pursue it.

Related posts:

T1International Statement on Appointments by President-elect Biden

T1International Statement on Appointments by President-elect Biden

On November 16, it was first reported that President-elect Biden will appoint Steve Ricchetti as one of his counselors in the White House. We are disappointed that the President-elect would choose a former lobbyist for Eli Lilly and Sanofi to serve in such a senior post in his administration. Read more

T1International Statement on Lawsuit to Overturn the Affordable Care Act

T1International Statement on Lawsuit to Overturn the Affordable Care Act

On November 10, the Supreme Court will hear oral arguments in California v. Texas, a case that could invalidate the Affordable Care Act (ACA). Since it was signed into law in 2010, the ACA has provided critical protections to the diabetes community in the United States. Now, a group of 18 states led by Texas are arguing that a single change to the law passed as part of the 2017 Tax Cuts and Jobs Act has rendered the entire law unconstitutional, even though there is no evidence that this was an outcome Congress intended at the time. If the Supreme Court rules in favor of Texas, the entire ACA could be ruled unconstitutional. Read more

T1International Statement on Executive Orders

T1International Statement on Executive Orders

On Friday afternoon, President Trump released four executive orders intended to lower drug prices, including two targeted directly at lowering the cost of insulin for patients who rely on it. Despite his assertion that these orders are intended to “completely restructure the prescription drug market,” these orders will not do anything to fix the underlying cause of the insulin crisis in America. Patients will still need to wait months for the rulemaking process to run its course, and likely even longer after that if these orders end up in court. While T1International USA is glad that the administration has stated that making insulin more affordable is a priority, these orders miss the mark. We don’t need incremental bureaucratic steps as an election approaches - we need transformative change that will make our medicine more affordable now. Read more

T1International Statement on Pharma’s Attempt to Block Minnesota’s Insulin Bill

T1International Statement on Pharma’s Attempt to Block Minnesota’s Insulin Bill

T1International is outraged, though not surprised, to see pharmaceutical companies once again put profit over human lives. On Tuesday, the Pharmaceutical Research and Manufacturers of America (PhRMA) filed a lawsuit against the state of Minnesota to challenge the Alec Smith Insulin Affordability Act. Read more